The CDISC TMF US Interchange conference was a pivotal event for trial master file (TMF) experts from a diverse array of organizations. This annual gathering brought together sponsors, TMF consultants, vendors, and auditors, creating a comprehensive and enriching experience for all attendees. Whether seasoned in the TMF requirements or new to the field, participants found value in the wide range of presentations and panel discussions tailored to various levels of expertise. A highlight of this edition was a special session with a Food and Drug Administration (FDA) inspector, offering unique insights into regulatory perspectives. Beyond the informative sessions, the event provided excellent networking opportunities and the chance to engage with TMF vendors.
Most Trending Topics
At the conference, the Reference Model Steering Committee generated significant excitement with the announcement of the upcoming Version 4.0 of the TMF Reference Model. This model is considered the biggest standard in the industry, especially for TMF. It could be compared to a cookbook for chefs or a music score for musicians. It serves as the recipe to ensure that TMFs are well structured and standardized. The last major version of this model was released almost 10 years ago, so the announcement of Version 4.0 for next year was warmly welcomed by all attendees.
New Reference TMF Model
The announcement highlighted that this would be the first TMF digital standard, aiming for all records to be born digital. Increased connectivity between the various systems in use was also emphasized, which is a welcome improvement given the multitude of systems currently in operation. Advancements in the standardization of metadata were discussed, ensuring easier transfer of TMFs between organizations or from CROs to sponsors at the end of studies. This new model is expected to address long-standing needs, such as integrating and standardizing the investigator site file within the TMF. Additionally, the model aims to clarify the filing of new records received from submission in Europe, particularly in relation to the European Clinical Trial Regulation (CTR). These enhancements are highly anticipated and should significantly benefit the industry.
Main Contributors
A call for volunteers was announced, inviting interested individuals to register on the CDISC website. Meetings will be held to gather opinions, with an expectation of active involvement from the TMF community. Ideas can also be submitted through a portal, and several suggestions were made during the conference. One idea was to add a Zone 12 to the TMF for filing system records. Another suggestion was to introduce a program level above the study level, which would allow for the filing of records applicable to multiple studies. Currently, the TMF has 3 levels: study, country, and site. Adding a program level would enhance organization. Additionally, some proposed assigning a risk level to each artifact. These suggestions highlight the community’s engagement and participation for the new version.
Insights From an FDA Inspector: Tips for Future Inspections
During the presentation, it was impressive to learn that over 400 sponsor inspections, including CRO inspections, were conducted by the FDA over the last 6 years. This highlights a very busy period for the FDA. The presentation by the inspector was particularly interesting, and 3 key takeaways can be shared with our listeners. First, the inspector emphasized the importance of presenting reliable data, which in terms of eTMF, means using a validated system from a qualified vendor and ensuring internal validation. Second, inspectors are increasingly requesting access to the TMF at the start of their inspections. CROs and sponsors need to be prepared with proper access rights and brief training on the system, as inspectors will expect this before being granted access. Finally, there is a growing focus on evidence of sponsor oversight. When sponsors delegate TMF responsibilities to CROs, inspectors may look for evidence that sponsors have been overseeing the CRO’s activities.
The Future of TMF
The risk-based approach is a prominent topic in the industry, and the TMF is no exception. Managing the TMF with this approach is not a one-size-fits-all solution; each organization must determine its own process. This approach should be applied to all steps of TMF management, not just quality control of documents. It can be used for inspection readiness reviews, audit trail reviews, audit trail reviews system validation, and user verification on a monthly or quarterly basis. Focusing on riskier areas at each step is essential.
In sum, the integration of artificial intelligence (AI) and machine learning into TMF management marks a significant advancement for the industry. Already aiding in tasks like document coding and classification, these technologies promise to further streamline processes by potentially handling parts of quality review and control in the future. This exciting development not only enhances efficiency but also ensures greater accuracy and consistency in managing trial master files. As AI and machine learning continue to evolve, their role in TMF management will undoubtedly become even more pivotal, driving the industry towards more innovative and effective practices.
Let’s shape the future of research and make a difference in the industry, gain Indero’s support in your upcoming trial and propel your study to new heights.
About the Author
Amélie Rivet, M.Sc.
Amélie Rivet is the Associate Director of eTMF Operations at Indero. With extensive experience as a clinical project manager, Amélie has successfully managed global trials across North America, Europe and Asia within the CRO environment. She possesses a deep understanding of all clinical phases, from start-up to close-out, and is well-versed in regulatory requirements. Amélie excels at managing multidisciplinary teams, ensuring the seamless execution and success of clinical trials.
